CR11399A - ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS - Google Patents

ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS

Info

Publication number
CR11399A
CR11399A CR11399A CR11399A CR11399A CR 11399 A CR11399 A CR 11399A CR 11399 A CR11399 A CR 11399A CR 11399 A CR11399 A CR 11399A CR 11399 A CR11399 A CR 11399A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
epithopes
formulations
bodies
Prior art date
Application number
CR11399A
Other languages
English (en)
Inventor
Dal Monte Paul
Giles-Komar Jill
Knight David
Khossravi Mehrnaz
Luo Jeffrey
Shealy David
Volkin David
Heavner George
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of CR11399A publication Critical patent/CR11399A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo anti-IL-12/23p40 que se une a una porcion de la proteina IL-12 o IL-23 que corresponde a la subunidad p40 de IL-12 o IL 23, que incluyen composiciones, formulas y metodos de administracion con aplicaciones en diagnostico y/o usos y dispositivos terapeuticos.
CR11399A 2007-09-28 2010-04-28 ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS CR11399A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
CR11399A true CR11399A (es) 2010-08-18

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11399A CR11399A (es) 2007-09-28 2010-04-28 ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS

Country Status (9)

Country Link
US (1) US20090181027A1 (es)
EP (1) EP2205276A4 (es)
CR (1) CR11399A (es)
EC (1) ECSP10010056A (es)
GT (1) GT201000073A (es)
HN (1) HN2010000573A (es)
NI (1) NI201000042A (es)
SV (1) SV2010003517A (es)
WO (1) WO2009114040A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201242976A (en) * 2011-01-07 2012-11-01 Abbott Lab Anti-IL-12/IL-23 antibodies and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA3037961A1 (en) * 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
WO2018181876A1 (ja) 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (en) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
BR112022001632A2 (pt) * 2019-07-30 2022-04-19 Akeso Biopharma Inc Anticorpos, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, conjugado de anticorpo, proteína de fusão, kit, usos do anticorpo, composição farmacêutica, métodos in vivo ou in vitro, para preparar o anticorpo e para prevenção, tratamento, tratamento adjuvante e/ou de diagnóstico de doenças autoimunes
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN115856281B (zh) * 2022-12-02 2025-06-03 北京世纪沃德生物科技有限公司 基于胶乳免疫比浊法测定il-12的试剂盒及方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
HUP0200575A3 (en) * 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
MY157915A (en) * 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤

Also Published As

Publication number Publication date
EP2205276A4 (en) 2012-08-15
WO2009114040A3 (en) 2010-05-27
ECSP10010056A (es) 2010-04-30
GT201000073A (es) 2012-04-19
SV2010003517A (es) 2010-08-10
HN2010000573A (es) 2012-12-10
EP2205276A2 (en) 2010-07-14
NI201000042A (es) 2010-09-13
US20090181027A1 (en) 2009-07-16
WO2009114040A2 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
MA33023B1 (fr) Formulation d'anticorps
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
ECSP077261A (es) Composición de anticuerpo her2
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
IL214325A (en) Antibody against cmet, a drug that includes and uses it
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
AR054474A1 (es) Formulacion de anticuerpos estables
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
CL2008002885A1 (es) Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
CR10561A (es) Vacunas para malaria
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
CR11585A (es) Vacunas para la malaria
DOP2005000210A (es) Antibony formulations
DE60111538D1 (de) Therapeutische verbindungen gegen eierstockkrebs
BRPI0503222A (pt) Formulações orais de paricalcitol
CY1115436T1 (el) Αναστολεις της κινασης p70 s6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)